📢 Great things ahead!
We’re thrilled to highlight the upcoming 7th EORTC #QualityofLife in Cancer Clinical Trials Conference, taking place 13–14 May 2027 in Madrid.
Proud to support this important event shaping the future of HRQOL and PRO research.👇
#QoLConf27 #CancerResearch #ClinicalTrials
👏 Proud to support the SISAQOL 2026 pilot in-person training together with the @qol.eortc.org — an excellent opportunity for hands‑on learning on PRO & HRQoL endpoints in cancer trials.
#SISAQOLtraining
📍Live from #EBCC15 in Barcelona!
As a proud partner of EBCC, EORTC is excited to be here and part of the conversation shaping the future of breast cancer care.
Come visit our booth to meet the team. We’d love to connect with you!
See you there 👋
#CancerResearch #ClinicalTrials #Oncology
🤝 Strengthening international collaboration to advance high‑quality patient‑centred outcomes research.
Proud to partner with Samsung Medical Center to further reinforce the quality of Korean versions of EORTC #QualityofLife questionnaires.
More info and link👇
#CancerResearch #GivingVoice2Patients
🎗️It’s #KidneyCancerAwarenessMonth, a moment to highlight progress in kidney cancer research.
Recently, we activated the first site for the RENALUT trial, advancing key research for metastatic clear cell renal cell carcinoma.
🔗Read more: www.eortc.org/blog/2026/02...
#EORTCgenitourinary
We’ve just wrapped up the EORTC 2026 Strategy Meeting!
Two inspiring days bringing global leaders together to strengthen independent, patient‑centred clinical cancer research.
Grateful for the collaboration and insight.
🔜 Stay tuned!
#EORTC #ClinicalResearch #CancerResearch
🆕 Published in The Oncologist:
New results from the SPARTA (GIMEMA–EORTC 1621‑QLG‑LG) study examine quality of life and lifestyle behaviours in long‑term AML survivors, offering essential insights for patient‑centred care.
🔗 www.eortc.org/publications/
#CancerResearch #AML #EORTC @qol.eortc.org
📩 MCCR 2026 Fellow notifications are on their way!
Keep an eye on your inbox, and don’t forget to check your spam folder just in case.
American Association for Cancer Research (AACR) ESMO - European Society for Medical Oncology #MCCR #CancerResearch #ClinicalTrialDesign
🚀 Join #EORTC as an Engagement & Partnerships Officer (Philanthropy)!
Build a pipeline of HNWIs, steward donors, support campaigns, and contribute to legacy giving.
3–6 yrs fundraising/relationship mgmt experience? Strong communicator?
👉 eortc.org/job/engageme...
#Hiring
💪 We continue our strong EORTC presence at #ESMORareCancers26, sharing new evidence on QoL, molecular profiling and treatment innovation in rare cancers.
Tomorrow, look out for Tetsuya Sekita’s poster on surgical quality in retroperitoneal liposarcoma.
#EORTC #RareCancers
This morning at #ESMORareCancers26, EORTC President Prof. Winette T. van der Graaf presented on advancing interventional research, noting:
“EORTC contributes to the EU Cancer Mission Forum for Rare Cancers, working towards a pan-European patient-centred solution.”
#EUHealth #CancerResearch
👏 EORTC is strongly represented today at the EU Cancer Mission Forum for Rare Cancers in Lugano, with President Winette van der Graaf CEO Denis Lacombe and taking part.
🚀 The 1st EORTC Summit in Clinical Cancer Research is coming!
AI, innovative methodologies, QOL, patient‑centricity, policy & more — all in one place.
📅 Save the date & help spread the word!
👉 www.eortc.org/summit
#EORTCSummit
👏 Proud to have our Scientific Director ,Saskia Litière, representing EORTC today at #ECR2026, contributing to the session on real‑world imaging biomarkers.
Great discussions on how imaging is evolving in clinical research and practice.
#EORTC #MedicalImaging #CancerResearch
🚀 New @eortc.org #QualityofLife Group review by Niclas Hubel et al. on the mode of assessment of questionnaires in cancer clinical trials: current practice & gaps in how questionnaires are assessed and need for better reporting.
🔗 doi.org/10.1007/s111...
#GivingVoice2Patients @msztankay.bsky.social
🎗️Tomorrow is #RareDiseaseDay.
Rare cancers represent 1 in 5 diagnoses and 1 in 3 cancer deaths.
Through its Rare Cancers Task Force, SPECTA & clinical trials, EORTC is advancing research and expanding treatment options for rare & ultra-rare cancers.
🔗 www.eortc.org/blog/2026/02...
📢 PEACE‑3 final results: adding radium‑223 to enzalutamide reduces risk of death by 24% in men with #mCRPC and bone metastases.
Results presented at ASCO @ascocancer.bsky.social #GU26 and published in Annals of Oncology.
🔗 Full press release: www.eortc.org/blog/2026/02...
#CancerResearch #PEACE3
EORTC has opened the first site for the #RENALUT study, launching a Phase II evaluation of [177Lu]Lu‑PSMA‑617 in metastatic clear cell renal cell carcinoma after progression on prior treatments. More sites across Europe will follow.
🔗Read more: www.eortc.org/blog/2026/02...
#ccRCC #CancerResearch
📣 Today at the German Cancer Congress, @eortc.org #QualityofLife Group highlights 3 important PRO projects: K. Taylor on #HNC survivorship; T. Nordhausen on TCIs for EORTC lung cancer module & PRO implementation in routine care.
www.deutscher-krebskongress.de
#DKK2026 @krebsgesellschaft.bsky.social
Today, EORTC CEO Denis Lacombe met with EU Health Commissioner Olivér Várhelyi to discuss the importance of independent clinical cancer research and the need for policies that support treatment optimisation and sustainable, patient‑centred cancer care in Europe.
#ClinicalTrials @ec.europa.eu
Over the past weeks, we shared stories from patients, advocates & researchers shaped by academic cancer research.
Thank you for following this journey. Together we can advance research and improve survival & quality of life.
Get involved 👉 www.eortc.org/impact
#WorldCancerDay #EORTCimpact
👏 Pleased to see the 2025 American Thyroid Association Guidelines emphasising the importance of validated #QualityofLife (QoL) measures and referring to the EORTC QLQ-THY34.
Disease-specific, validated tools are key to better understanding patients’ lived experience and QoL in #ThyroidCancer care. 👇
Happy International Day of Women & Girls in Science!
At EORTC, we celebrate the women advancing cancer research. 💡
Prof Piccart helped lead MINDACT, transforming breast cancer care and reducing unnecessary chemotherapy.
Find out more: www.eortc.org/impact/
#EORTCimpact
👉 In case you missed it, we’ve created a new webpage dedicated to EORTC’s impact over the last 60 years.
Discover more: www.eortc.org/impact
#WorldCancerDay #ClinicalTrials #EORTCimpact #CancerResearch #LeavingNoCancerPatientBehind
📢 Registrations are now open!
💻 Clinical Trial Statistics for Non-Statisticians course introduces the statistical methods used in the design, conduct and analysis of cancer clinical trials.
📅 Dates: 9-12 June 2026
👉 Register now: https://www.eortc.org/event/stats2026/
🎗️This World Cancer Day, we’re proud to share how the EORTC-led MINDACT study helped change breast cancer care worldwide.
Hear from patient Betty & Prof Piccart.
🔗 www.eortc.org/blog/2026/02...
A big thank you to everyone involved in this study!
#WorldCancerDay #EORTCimpact
🎓 ESOI–EORTC Workshop 2026
Interactive lectures and hands on workshops on imaging based tumour response assessment.
Designed for practising radiologists and radiology residents, with real life cancer cases from routine care and clinical trials.
🔗 https://www.esoi-society.org/esoi-eortc-2026/
🎗️Tomorrow is World Cancer Day.
We’ll be sharing Betty’s story, a patient whose experience with the MINDACT study shows how clinical cancer research can change lives.
🎬 Don’t miss it!
#WorldCancerDay #LeavingNoCancerPatientBehind #EORTCimpact #ClinicalTrials
Practice-changing research means results that directly transform patient care.
This World Cancer Day, EORTC will highlight MINDACT, a study that has changed the standard of care for breast cancer.
📅 Stay tuned!
#WorldCancerDay #ClinicalTrials #EORTCimpact #CancerResearch #CancerSurvivor
